Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘后交易 05-03 17:11:21 EDT

76.97

+1.21

+1.60%

盘后77.00

+0.03+0.04%

17:10 EDT

最高77.68	最低72.88	成交量374.87万
今开74.49	昨收75.76	日振幅6.34%
总市值84.84亿	流通市值80.24亿	总股本1.10亿
成交额2.85亿	换手率3.60%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":76.97,"timestamp":1714766400000,"preClose":75.76,"halted":0,"volume":3748745,"hourTrading":{"tag":"盘后","latestPrice":77,"preClose":76.97,"latestTime":"17:10 EDT","volume":66552,"amount":5120788.801152,"timestamp":1714770620475},"delay":0,"floatShares":104246934,"shares":110228869,"eps":-0.931395,"marketStatus":"盘后交易","marketStatusCode":4,"change":1.21,"latestTime":"05-03 17:11:21 EDT","open":74.49,"high":77.68,"low":72.88,"amount":284806290.41865003,"amplitude":0.063358,"askPrice":77.5,"askSize":100,"bidPrice":76.5,"bidSize":66,"shortable":3,"etf":0,"ttmEps":-0.931395,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714780800000},"adr":0,"listingDate":1430280000000,"adjPreClose":75.76,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":74.15,"preClose":75.76,"latestTime":"09:29 EDT","volume":61119,"amount":4458424.773375,"timestamp":1714742985069},"postHourTrading":{"tag":"盘后","latestPrice":77,"preClose":76.97,"latestTime":"17:10 EDT","volume":66552,"amount":5120788.801152,"timestamp":1714770620475},"volumeRatio":1.144974},"requestUrl":"/m/hq/s/VKTX/","defaultTab":"news","newsList":[{"id":"2432954927","title":"BUZZ-竞争对手安进公司对中期减肥药物数据表示 \"满意\"，维京下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2432954927","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432954927?lang=zh_cn&edition=full","pubTime":"2024-05-03 19:00","pubTimestamp":1714734027,"startTime":"0","endTime":"0","summary":"** 竞争对手安进  周四晚些时候表示， ，其实验性减肥药MariTide的中期研究的中期安全性和有效性数据令其 \"非常满意\"。** AMGN股价盘前上涨14.1%至317.65美元，该公司预计将在今年晚些时候公布MariTide的中期数据。** 在一项研究中，VKTX公司的注射减肥药平均帮助患者减轻了近15%的体重  ** 减肥药市场领军企业百合  盘前股价下跌2%，诺和诺德  下跌4%。** 截至上次收盘，VKTX 的股价今年已翻了两番多** 今年以来，AMGN下跌3.3%，LLY上涨约30%，诺和诺德上涨约20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432070323","title":"Viking Therapeutics, Inc.盘中异动 急速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432070323","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432070323?lang=zh_cn&edition=full","pubTime":"2024-05-01 02:28","pubTimestamp":1714501690,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日02时28分，Viking Therapeutics, Inc.股票出现波动，股价快速上涨5.06%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Cyclacel Pharmaceuticals, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Eliem Therapeutics, Inc涨幅较大，Cyclacel Pharmaceuticals, Inc.、Biorestorative Therapies, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为1516.53%、236.35%、29.76%，振幅较大的相关个股有Eliem Therapeutics, Inc、Lexaria Bioscience Corp C/Wts 14/01/2026 、Cassava Sciences Inc C/Wts 15/11/2024，振幅分别为55.38%、48.00%、46.79%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240501022810861ea7ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240501022810861ea7ba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430789660","title":"Viking Therapeutics, Inc.盘中异动 快速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430789660","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430789660?lang=zh_cn&edition=full","pubTime":"2024-04-27 01:20","pubTimestamp":1714152030,"startTime":"0","endTime":"0","summary":"北京时间2024年04月27日01时20分，Viking Therapeutics, Inc.股票出现波动，股价快速上涨5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。该信息摘要如下：HC Wainwright & Co.：重申Viking Therapeutics评级，由买入调整至买入评级, 目标价90.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270120307a565087&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270120307a565087&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430239027","title":"Viking Therapeutics, Inc.2024财年第一财季实现净利润-27.36百万美元，同比减少40.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430239027","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430239027?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:15","pubTimestamp":1714061728,"startTime":"0","endTime":"0","summary":"3月31日，Viking Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-27.36百万美元，同比减少40.09%；其中营业收入为0.00美元，每股基本收益为-0.26美元。从资产负债表来看，Viking Therapeutics, Inc.总负债33.63百万美元，其中短期债务329000.00美元，资产负债比为0.29，流动比率为0.30。机构评级：截至2024年3月31日，当前有11家机构对Viking Therapeutics, Inc.目标价做出预测，其中目标均价为112.26美元，其中最低目标价为90.00美元，最高目标价为138.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042600153587aff46b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042600153587aff46b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430284074","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.12%报68.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430284074","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430284074?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:09","pubTimestamp":1714054166,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时09分，Viking Therapeutics, Inc.股票出现异动，股价急速上涨5.12%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.76%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。该信息摘要如下：HC Wainwright & Co.：重申Viking Therapeutics评级，由买入调整至买入评级, 目标价90.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252209267a55b6d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252209267a55b6d7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430289033","title":"BUZZ-季度亏损低于预期，维京公司业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430289033","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430289033?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:03","pubTimestamp":1714053797,"startTime":"0","endTime":"0","summary":"    4月25日 - ** 药物开发商Viking Therapeutics   股价上涨2.5%至66.68美元 **  第一季度亏损26美分/每小时，分析师平均预期亏损28美分/每小时 - LSEG数据** 3月份，该公司的实验性片剂在参加小型早期试验的志愿者中进行了测试，结果显示，  重量减轻了3.3%。** Truist 分析师 Joon Lee 说：\"VKTX 现在是一家相当低风险的生物技术公司，在生物技术领域经营肥胖症业务。** 包括本交易日的走势在内，该公司股价今年已上涨了一倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430967402","title":"HC Wainwright & Co.：重申Viking Therapeutics(VKTX.US)评级，由买入调整至买入评级, 目标价90.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430967402","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430967402?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:26","pubTimestamp":1714044367,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Viking Therapeutics(VKTX.US)评级，由买入调整至买入评级, 目标价90.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042519260987af0895&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042519260987af0895&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429119748","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429119748","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429119748?lang=zh_cn&edition=full","pubTime":"2024-04-23 23:00","pubTimestamp":1713884447,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日23时00分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.65%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232300477a54f246&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232300477a54f246&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429771900","title":"Viking Therapeutics Inc    预计每股亏损 28 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429771900","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429771900?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:02","pubTimestamp":1713826938,"startTime":"0","endTime":"0","summary":"   * Viking Therapeutics Inc    将于4月24日公布截至2024年3月31日的财报，预计季度收入将保持不变。*    * LSEG分析师对Viking Therapeutics Inc的平均预期是每股亏损28美分。* 华尔街对 Viking Therapeutics Inc 的 12 个月目标价中位数为 115.00 美元，高于其上次收盘价 63.85 美元。4月22日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428790561","title":"减肥药开发商 Metsera 获得 2.9 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2428790561","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428790561?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:09","pubTimestamp":1713438543,"startTime":"0","endTime":"0","summary":"Metsera公司由风险投资公司ARCH Venture和投资公司Population Health Partners于2022年成立，目前正在开发基于GLP-1机制和其他生物靶点的治疗肥胖症的注射和口服药物。Meanwell 说，Metsera 的 2.9 亿美元融资是迄今为止从领先的医疗保健投资者银团筹集到的资金总额，包括种子轮和 A 轮融资。Meanwell 拒绝就融资的估值发表评论。Meanwell曾担任The Medicines Company首席执行官近20年，该公司于2019年被瑞士制药商诺华  以97亿美元收购， 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426111794","title":"Viking Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%报72.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426111794","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426111794?lang=zh_cn&edition=full","pubTime":"2024-04-09 23:35","pubTimestamp":1712676945,"startTime":"0","endTime":"0","summary":"北京时间2024年04月09日23时35分，Viking Therapeutics, Inc.股票出现波动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Acrivon Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Syros Pharmaceuticals, Inc.涨幅较大，Mymd Pharmaceuticals, Inc.、Biophytis、Acrivon Therapeutics, Inc.较为活跃，换手率分别为459.92%、105.59%、82.91%，振幅较大的相关个股有Mymd Pharmaceuticals, Inc.、Biophytis、Cadrenal Therapeutics, Inc.，振幅分别为45.14%、40.61%、39.14%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040923354587e7ee92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040923354587e7ee92&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425992595","title":"Viking Therapeutics, Inc.盘中异动 急速上涨5.05%报77.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425992595","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425992595?lang=zh_cn&edition=full","pubTime":"2024-04-06 01:19","pubTimestamp":1712337543,"startTime":"0","endTime":"0","summary":"北京时间2024年04月06日01时19分，Viking Therapeutics, Inc.股票出现波动，股价大幅拉升5.05%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.26%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240406011903791edc2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240406011903791edc2d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425349231","title":"Viking Therapeutics, Inc.盘中异动 下午盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425349231","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425349231?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:15","pubTimestamp":1712254559,"startTime":"0","endTime":"0","summary":"北京时间2024年04月05日02时15分，Viking Therapeutics, Inc.股票出现异动，股价急速跳水5.07%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Candel Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Tc Biopharm  Plc涨幅较大，Tc Biopharm  Plc、Candel Therapeutics, Inc.、Effector Therapeutics, Inc.较为活跃，换手率分别为3482.49%、276.26%、216.74%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Candel Therapeutics, Inc.、Tc Biopharm  Plc，振幅分别为133.46%、116.07%、111.54%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050215597a510884&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050215597a510884&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424232043","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424232043","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424232043?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:40","pubTimestamp":1712065201,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时40分，Viking Therapeutics, Inc.股票出现波动，股价大幅下挫5.04%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.33%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。消息层面，截至21时40分，《维京治疗来势汹汹，但撼动礼来、诺和诺德江湖地位仍为时尚早》资讯为影响Viking Therapeutics, Inc.的重要信息。智通财经APP了解到，目前，维京治疗Viking Therapeutics的 VK2735 已成为 GLP-1 药物市场的有力竞争者，在临床研究中取得了良好的减肥效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022140027a50b625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404022140027a50b625&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1134994137","title":"维京治疗来势汹汹，但想撼动礼来、诺和诺德仍为时尚早","url":"https://stock-news.laohu8.com/highlight/detail?id=1134994137","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/1134994137?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:48","pubTimestamp":1711968535,"startTime":"0","endTime":"0","summary":"制药和生物技术行业争相开发GLP-1药物，维京治疗成为最有力竞争者。","market":"us","thumbnail":"https://static.tigerbbs.com/13979f39d2d97a07bd73c546f6da4b71","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/13979f39d2d97a07bd73c546f6da4b71"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1097148.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2422751997","title":"Viking Therapeutics, Inc.盘中异动 早盘急速拉升5.01%报84.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751997","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422751997?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:33","pubTimestamp":1711546404,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日21时33分，Viking Therapeutics, Inc.股票出现异动，股价快速上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Hoth Therapeutics, Inc.较为活跃，换手率分别为951.03%、445.08%、50.05%，振幅较大的相关个股有Ibio, Inc.、Apollomics Inc C/Wts 01/04/2028 、Lixte Biotechnology Holdings, Inc.，振幅分别为41.74%、27.59%、25.94%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422987585","title":"港股概念追踪 |Viking(VKTX.US)创新口服减肥疗法临床结果积极 减肥药受关注（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2422987585","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422987585?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:42","pubTimestamp":1711507367,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月26日，Viking Therapeutics公司宣布，该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果，接受最高剂量治疗的参与者在28天后体重减少5.3%。根据弗若斯特沙利文的报告，全球减肥药物市场规模从2016 年的18亿美元增长到2020年的26亿美元，年复合增长率为9.0%。值得一提是，目前体重管理适应症的相关药物在国内尚未批准上市，联邦制药是国内首家获得该生物类似物临床批件的企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422603210","title":"4周体重下降近10斤！Viking(VKTX.US)创新口服减肥疗法临床结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2422603210","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422603210?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:48","pubTimestamp":1711500536,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月26日，Viking Therapeutics公司宣布，该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果，接受最高剂量治疗的参与者在28天后体重减少5.3%。这项为期28天的剂量递增研究结果突显了口服VK2735治疗的积极临床活性。口服VK2735显示出良好的安全性和耐受性。Viking还计划在2024年下半年，针对肥胖患者启动口服VK2735的2期试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093079.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1110387722","title":"昨夜今晨 | 官宣利好，“减肥药新贵”Viking飙升近17%；英伟达尾盘跳水，特斯拉逆市涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110387722","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1110387722?lang=zh_cn&edition=full","pubTime":"2024-03-27 07:34","pubTimestamp":1711496082,"startTime":"0","endTime":"0","summary":"“减肥药新贵”Viking飙涨逾17%隔夜美股三大股指尾盘跳水，截至收盘，标普500跌0.28%，报5203.58点；纳斯达克指数跌0.42%，报16315.7点；道琼斯工业指数跌0.08%，报39282.33点。超级科技巨头多数走弱，英伟达冲高乏力尾盘跳水跌超2%，META跌超1%，苹果、微软、亚马逊微跌，特斯拉逆市涨近3%。截至发稿，特斯拉的全自动驾驶功能售价为12000美元。叠加商讨意大利建厂的消息影响，特斯拉周二一度涨超6%，收盘时涨幅","market":"us","thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1002},{"period":"1month","weight":-0.0206},{"period":"3month","weight":2.2307},{"period":"6month","weight":6.181},{"period":"1year","weight":2.5319},{"period":"ytd","weight":3.0709}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.031825},{"month":2,"riseRate":0.555556,"avgChangeRate":0.264573},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020024},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000523},{"month":5,"riseRate":0.3,"avgChangeRate":0.111331},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.009265},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014001},{"month":8,"riseRate":0.444444,"avgChangeRate":0.019922},{"month":9,"riseRate":0.333333,"avgChangeRate":0.070513},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.002105},{"month":11,"riseRate":0.555556,"avgChangeRate":0.0115},{"month":12,"riseRate":0.666667,"avgChangeRate":0.206888}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}